

Secretoneurin Publications

1. **Secretoneurin as a novel cardiovascular biomarker and potential therapeutic strategy.**
[Ottesen, A. H., Røsjø, H., & Omland, T.](#)
[2026 Expert Review of Cardiovascular Therapy, 24\(1\), 21–27.](#)
2. **Serial secretoneurin measurement and risk of ventricular arrhythmias and death in patients with left ventricular systolic dysfunction.**
[Omland, T., Røsjø, H., Wisløff, T., Bernard, M. L., Hiltbold, A. E., Khatib, S., Polin, G. M., Rogers, P. A., & Morin, D. P.](#)
[2025 Clinical Biochemistry, 135, 110868.](#)
3. **Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study.**
[Røsjø, H., Rugolo, I., Gjørven, A., Faaren, A. L., Frantzen, F., Christensen, G., Høiseth, A. D., Ottesen, A. H., Bhatnagar, R., Lyngbakken, M. N., & Omland, T.](#)
[2025 The Journal of Applied Laboratory Medicine, 10\(3\), 691–703.](#)
4. **Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial.**
[Helge Røsjø, Jennifer Meessen, Anett Hellebø Ottesen, Roberto Latini, Torbjørn Omland, on behalf of the GISSI-HF Investigators](#)
[2023 Clinical Biochemistry 118](#)
5. **Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure.**
[H. Rosjo, J. Meessen, A.H. Ottesen, R. Latini, T. Omland, on behalf of GISSI-HF Study](#)
[2022 European Heart Journal, Volume 43, Issue Supplement 2](#)
6. **Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis.**
[Kristin M. Aakre, Anett H. Ottesen, Heidi Strand, Arne L. Faaren, Bashir Alaour, Janniche Torsvik, Marit S. Sylte, Michael Marber, Geir Christensen, Helge Røsjø, Torbjørn Omland](#)
[2021 Clin Biochem](#)
7. **Circulating secretoneurin concentrations are increased in patients with acute coronary syndrome and provide prognostic information.**
[P. Myhre, A.H. Ottesen, A.L. Faaren, S.H. Tveit, J. Springett, J. Pyylampi, M. Stridsberg, G. Christensen, T. Omland, H. Rosjo](#)
[2020 European Heart Journal, Volume 41, Issue Supplement 2](#)
8. **Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca²⁺- Dependent Arrhythmia.**
[Ottesen, A. H., Carlson, C. R., Eken, O. S., Sadredini, M., Myhre, P. L., Shen, X., Dalhus, B., Laver, D. R., Lunde, P. K., Kurola, J., Lunde, M., Hoff, J. E., Godang, K., Sjaastad, I., Pettilä, V., Stridsberg, M., Lehnart, S. E., Edwards, A. G., Lunde, I. G., ... Louch, W. E.](#)
[2019 Circulation: Arrhythmia and Electrophysiology, 12\(4\), e007045.](#)
9. **Secretoneurin to the Rescue?**
[Morrow, J. P., & Marx, S. O.](#)
[2019 Circulation: Arrhythmia and Electrophysiology, 12\(4\), e007298.](#)